Fibrocell Science Inc (FCSC.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|48||2016||Chairman of the Board|
|42||2017||President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer|
|2017||Vice President - of Corporate Accounting , Controller|
|2018||Vice President - Business Development, Corporate Secretary|
|66||2013||Lead Independent Director|
- BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa
- BRIEF-Fibrocell Reports Q1 Loss Per Share $0.11
- BRIEF-Fibrocell Announces Review Of Strategic Alternatives
- BRIEF-Fibrocell Reports 2017 Financial Results And Recent Highlights
- BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013